Development of Seasonal Influenza Virus-like Particle (VLP) Vaccines Using Insect Cell-based Baculovirus Expressing System;用昆蟲細胞衍生類病毒顆粒生產平台開發季節性流感疫苗

NCUIR > college of Health Sciences and Technology > Graduate Institute of Life Science > Electronic Thesis & Dissertation > Item 987654321/94752

Please use this identifier to cite or link to this item: http://ir.lib.ncu.edu.tw/handle/987654321/94752

Title:	Development of Seasonal Influenza Virus-like Particle (VLP) Vaccines Using Insect Cell-based Baculovirus Expressing System;用昆蟲細胞衍生類病毒顆粒生產平台開發季節性流感疫苗
Authors:	艾提曼;BADRUZZAMAN, A T M
Contributors:	生命科學系
Date:	2024-07-30
Issue Date:	2024-10-09 15:27:52 (UTC+8)
Publisher:	國立中央大學
Abstract:	季節性流感病毒對全球健康構成重大威脅，迫切需要有效的預防策略。疫苗接種仍然是預防的基石，但當前的方法主要依賴於使用胚胎雞蛋（ECE）生產的滅活裂解病毒疫苗，此方法存在各種缺點，包括過敏反應、血凝素（HA）基因的適應性突變、蛋供應中斷以及生產放大問題。為了克服對 ECE的依賴，極需利用高效和穩定生產平台來開發流感疫苗。已經有幾個疫苗生產系統顯示出作為替代品的潛力，包括類病毒顆粒（VLP）平台。在這項研究中，我們使用桿狀病毒表達系統（BES），選殖流感 A/H1N1、A/H3N2、 B/Yamagata-like 和 B/Victoria-like 病毒株（ A/Hawaii/70/2019, A/Minnesota/41/2019, B/Brisbane/09/2014 & B/Brisbane/63/2014）的 HA、NA 和 M1 基因，以生產 VLP 疫苗抗原 H1N1-VLP、H3N2-VLP、Yamagata-VLP 和 Victoria-VLP，因此四種 homologus VLP 的 HA 抗原產量差距四倍以上。然後，我們開發了嵌合 VLP，以提高 HA 蛋白的產量。我們評估了它們的功能和抗原特性，包括凝血試驗、蛋白組成、形態學、穩定性和免疫原性。我們發現，同源和嵌合 VLP 的功能活性`形態和大小上類似於流感病毒顆粒，同時保持結構完整性。小鼠的免疫原性比較評估顯示，我們的四價 VLP在誘導凝血抑制抗體、中和抗體與上市的雞胚蛋及重組蛋白疫苗相比具有優越性，並對同源病毒提供 100%的保護。這些發現表明，昆蟲細胞產出的 VLP疫苗作為四價季節性流感疫苗的候選者具有良好的商業潛力，值得進一步開發。 ;Seasonal influenza viruses pose a significant threat to global health, necessitating effective prevention strategies. While vaccination remains the cornerstone, current methods primarily rely on inactivated split virus vaccines generated using embryonated chicken eggs (ECE), present various drawbacks including allergic reactions, adaptive mutation in hemagglutinin (HA) gene, disruptions in egg supply, and scalability issues. To overcome the dependency on ECE, developments of influenza vaccines based on efficient and robust production platforms are urgently needed. Several potential vaccine production systems have shown potential as replacers, including a virus-like particle (VLP) platform. In this study, using a Baculovirus Expression System (BES), we engineered HA, NA, and M1 genes of influenza A/H1N1, A/H3N2, B/Yamagata-like, and B/Victoria-like virus strains (A/Hawaii/70/2019, A/Minnesota/41/2019, B/Brisbane/09/2014 & B/Brisbane/63/2014) to produce VLP vaccine antigens H1N1-VLP, H3N2-VLP, Yamagata-VLP, Victoria-VLP, respectively. We then assessed their functional and antigenic characteristics, including hemagglutination assay, protein composition, HA protein productivity, VLPs morphology, stability and immunogenicity. We found that recombinant VLPs displayed functional activity, resembling influenza virions in morphology and size, while maintaining structural integrity. Comparative immunogenicity assessments in mice showed that our quadrivalent VLPs were consistent in inducing hemagglutination inhibition (HAI) and neutralizing (NT) antibody titers against homologous viruses compared to both commercial recombinant HA (Flublok) and egg-based vaccines (Vaxigrip). Since the HA antigen yields of the homologous VLPs varied more than four folds, we further developed chimeric VLPs to improve HA protein production and address the limitations of the homologous VLPs. We assessed their antigenic characteristics, comparative HA protein productivity, immunogenicity and vaccine efficacy. We found that similar to homologous VLPs, chimeric VLPs displayed functional activity, resembling influenza virions in morphology and size. Comparative immunogenicity assessments in mice showed that the VLP vaccine consistent in inducing higher hemagglutination inhibition and neutralizing antibody titers and provided 100% protection against homologous viruses compared to the commercial vaccine. The findings highlight insect cell-based VLP vaccines as promising candidates for quadrivalent seasonal influenza vaccines.
Appears in Collections:	[Graduate Institute of Life Science] Electronic Thesis & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	31	View/Open

社群 sharing

Loading...